Sheets Smith Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Sheets Smith Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$44.2K	Buy	+20,390	New	+$48.1K	0.03%	135

Other funds holding IOVA

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sheets Smith Investment Management's IOVA Position: Q3 2025 in Review

Sheets Smith Investment Management opened a new position in Iovance Biotherapeutics (IOVA) in Q3 2025: 20,390 shares worth $44.2K. The stake represents 0.03% of the portfolio and ranks #135 among its holdings.

253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

Sheets Smith Investment Management held 20,390 shares of Iovance Biotherapeutics worth $44.2K as of Q3 2025.
Iovance Biotherapeutics was a new Sheets Smith Investment Management position in Q3 2025.
Iovance Biotherapeutics made up 0.03% of Sheets Smith Investment Management's portfolio in Q3 2025, its #135 holding.
253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Sheets Smith Investment Management's 13F filing for Q3 2025, filed 8 Oct 2025.